GlassScriptPhysician profile
Isaac Victor
NPI 1073678280
$5,486.32
in general payments reported to CMS, 2019-2025
27 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 85% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $880 · 2021: $766 · 2022: $934 · 2023: $592 · 2024: $637 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,239 · Education: $58.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,239.31 |
| Education | $58.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $1,688.15 | 2019-2025 | Slynd, Tyblume, Nuvessa |
| Sumitomo Pharma America, INC. | $599.10 | 2024-2025 | Myfembree, Gemtesa |
| Abbvie INC. | $400.27 | 2019-2025 | Lo Loestrin Fe, Botox |
| Mayne Pharma Commercial LLC | $368.67 | 2021-2025 | |
| Lupin INC. | $364.87 | 2019-2021 | |
| Celularity INC. | $300.00 | 2020 | |
| Agile Therapeutics, INC. | $194.21 | 2021-2022 | |
| Myovant Sciences INC. | $191.72 | 2021-2022 | |
| Coopersurgical, INC. | $189.30 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Organon LLC | $174.50 | 2022-2025 | Nexplanon |
| Evofem Biosciences, INC. | $166.58 | 2020-2023 | Phexxi |
| Avion Pharmaceuticals | $166.45 | 2019-2023 | Balcoltra |
| Allergan, INC. | $142.50 | 2019-2022 | |
| Scynexis, INC. | $99.52 | 2022 | |
| Millicent US INC | $83.13 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $81.20 | 2019-2024 | Aptima |
| Therapeuticsmd, INC. | $59.53 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $52.33 | 2019-2021 | |
| Pfizer INC. | $39.46 | 2021-2022 | |
| Astellas Pharma US INC | $30.41 | 2024-2025 | Veozah |
| Vertical Pharmaceuticals, LLC | $27.75 | 2019 | |
| Mission Pharmacal Company | $15.33 | 2023 | Citranatal |
| Daiichi Sankyo INC. | $14.40 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.69 | 2020 | |
| Mylan Pharmaceuticals INC. | $13.10 | 2020 | |
| Meditrina | $8.84 | 2023 | |
| Alydia Health | $1.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Victor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.